SDS Optic optical coatings subpage

Investor relations

Company profile

SDS Optic S.A. develops innovative products for medical diagnostics. Its flagship project is inPROBE, a fiber-optic microsensor for oncology biomarker diagnostics.

Strategy and Business Model
Market Landscape
SDS Optic calendar for periodic reports in 2026

Investor's calendar

Schedule of periodic report publications in 2026:

Quarterly report for Q4-2025 – February 12, 2026

Quarterly report for Q1-2026 – May 14, 2025

Quarterly report for Q2-2026 – August 13, 2026

Quarterly report for Q3-2026 – November 10, 2026

Annual report for 2025 – June 1, 2026

IR

Contact for investors

Marketing, Communications and IR Team

+48 81 501 94 63ir@sdsoptic.comFrequently asked questions

Stock quote

The company has been listed on the NewConnect market of the Warsaw Stock Exchange since March 15, 2022

Sector: medical equipment and supplies

ISIN: PLSDSO00013

Ticker: SDS

Learn more
SDS Optic shareholder structure

Shareholder structure

based on the information held by the Company

SDS Optic shareholders structure
View each share series

SDS Optonic Sp. z o.o. is an entity controlled by Marcin Staniszewski, President of the Management Board of the Issuer. As of the date of publication of this report, he—together with his spouse and the financial shareholders of SDS Optonic Sp. z o.o.—holds a total of 2,643,860 shares in the Company, representing 39.61% of the Company’s share capital and conferring the right to exercise 2,643,860 votes at the General Meeting of the Issuer, i.e., 39.61% of the total number of votes in the Company. Marcin Staniszewski individually holds rights to 1,282,934 shares of the Issuer, representing 19.22% of the Company’s share capital. The remaining shareholders of SDS Optonic Sp. z o.o. are entitled to 1,147,826 shares of the Issuer, representing 17.9% of the Company’s share capital. According to the information available to the Company, Paweł Kania and Ewa Kania are spouses and, pursuant to Article 87(4)(1) of the Act on Public Offering, are presumed to be acting in concert with respect to holding shares in the Company and exercising voting rights attached to those shares. The total shareholding of the spouses acting in concert amounts to 681,200 shares, representing 10.20% of the Company’s share capital and conferring 10.20% of the total number of votes at the General Meeting. Of this amount, Paweł Kania directly holds 667,300 shares, representing 9.996% of the share capital and voting rights, while Ewa Kania directly holds 13,900 shares, representing 0.21% of the share capital and voting rights.

SDS Optic group Structure

SDS Optic Group Capital Structure

As of the end of December 2024, SDS Optic S.A. is the parent company of two subsidiaries, FiBioMed Sp. z o.o. and SDS Optic Inc., in which it holds majority stakes

FiBioMed Sp. z o.o.– a company established to work on the development of fiber optic technologies in the field of infectious diseases. These activities are carried out based on a license agreement signed with SDS Optic S.A. SDS Optic S.A. holds 579 shares in FiBioMed Sp. z o.o. with a nominal value of PLN 28,950.00, representing 82.7% of the company’s share capital.

SDS Optic Inc. (USA) is an R&D center in Philadelphia, established to develop technologies in the field of cancer biomarker and eye disease diagnostics by creating biological components of the technology. SDS Optic S.A. holds 100% of the share capital of SDS Optic Inc.

Authorized Advisor and Market Animator

Authorized Advisor

Navigator logo

Navigator Capital S.A.

18 Twarda Street, Warsawbiuro@navigatorcapital.plhttps://navigatorcapital.pl/+48 22 630 83 33

Market Animator

Navigator logo

DM BOŚ

78/80 Marszałkowska St, Warsawmakler@bossa.plhttps://bossa.pl/+48 22 504 31 04

We Care About Your Privacy

SDS Optic S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.